Unfractioned Heparin for Treatment of Sepsis Caused by Abdominal Infection

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-05-11

Study Completion Date

2024-07-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Sepsis is the leading cause of death in intensive care units and a major public health concern in the world. Heparin, a widely used anticoagulant medicine to prevent or treat thrombotic disorders, has been demonstrated to prevent organ damage and lethality in experimental sepsis models. However, the efficacy of heparin in the treatment of clinical sepsis is not consistent. Caspase-11, a cytosolic receptor of LPS, triggers lethal immune responses in sepsis. Recently, we have revealed that heparin prevents cytosolic delivery of LPS and caspase-11 activation in sepsis through inhibiting the heparanase-mediated glycocalyx degradation and the HMGB1- LPS interaction, which is independent of its anticoagulant properties. In our study, it is found that heparin treatment could prevent lethal responses in endotoxemia or Gram-negative sepsis, while caspase-11 deficiency or heparin treatment failed to confer protection against sepsis caused by Staphylococcus aureus, a type of Gram-positive bacterium. It is probably that other pathogens such as Gram-positive bacteria might cause death through mechanisms distinct from that of Gram-negative bacteria. Peptidoglycan, a cell-wall component of Gram-positive bacteria, can cause DIC and impair survival in primates by activating both extrinsic and intrinsic coagulation pathways, which might not be targeted by heparin. We speculate that the discrepancy between the previous clinical trials of heparin might be due to the difference in infected pathogens. Thus, stratification of patients based on the type of invading pathogens might improve the therapeutic efficiency of heparin in sepsis, and this merits future investigations.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety of Heparin in Patients With Septic Shock

NCT01234285

Sepsis

WITHDRAWN PHASE2

Efficacy and Safety of Unfractionated Heparin on Severe Sepsis With Suspected Disseminated Intravascular Coagulation

NCT02654561

Sepsis Disseminated Intravascular Coagulation

RECRUITING PHASE3

Impact of Low Dose Unfractionated Heparin Treatment on Inflammation in Sepsis

NCT02135770

Severe Sepsis With Septic Shock Severe Sepsis Without Septic Shock

COMPLETED PHASE3

Albumin Infusion Targets on Mortality in Patients With Abdominal Sepsis

NCT06874634

28-day Mortality

COMPLETED

Efficacy of Anisodamine Hydrobromide Combined With Low-molecular-weight Heparin in the Treatment of Patients With Sepsis

NCT05634057

Sepsis

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In clinical patients, the major pathogens of sepsis caused by abdominal infection are mostly Gram-negative bacterium. Therefore, aim of this study is to determine effects of low dose unfractionated heparin for treatment of sepsis caused by abdominal infection.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sepsis Gram-Negative Bacterial Infections Heparin

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Unfractionated Heparin

A bottle solution of Heparin Sodium (2ml:12500IU) is added to 48 ml saline and administered intravenously continuously for 24 hours (10 unit/kgBW/hour), which last 5 days or until the death or discharge.

Group Type EXPERIMENTAL

Unfractionated Heparin

Intervention Type DRUG

10 unit/kgBW/hour continuous infusion for 5 days

Normal saline

The same amount of 0.9% saline as the heparin group (50ml) will be administered in the placebo group.

Group Type PLACEBO_COMPARATOR

Unfractionated Heparin

Intervention Type DRUG

10 unit/kgBW/hour continuous infusion for 5 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Unfractionated Heparin

10 unit/kgBW/hour continuous infusion for 5 days

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Heparin sodium

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1.Sepsis-3 criteria from Society of Critical Care Medicine (SCCM) /European Society of Intensive Care Medicine (ESICM), and the infection site is from abdomen 2.18≤ age ≤75years 3.obtain informed consent

Exclusion Criteria

1. The primary site of infection is from other parts (such as lungs, intracranial, etc.) except abdomen
2. Diagnosis of sepsis for more than 48 hour
3. Pregnant and lactating women
4. Severe primary disease including unrespectable tumours, blood diseases and Human Immunodeficiency Virus (HIV);
5. Have a known or suspected adverse reaction to UFH including HIT
6. Have bleeding or high risk for bleeding
7. Have an indication for therapeutic anticoagulation or have taken anticoagulants within 7 days
8. Use of an immunosuppressant or having an organ transplant within the previous 6 months
9. Participating in other clinical trials in the previous 30 days
10. Have received cardiopulmonary resuscitation within 7 days
11. Have terminal illness with a life expectancy of less than 28 days

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No